Frost & Sullivan independent industry report identifies PromarkerD as the world leading test for Diabetic Kidney Disease
SHANGHAI, Mar 27, 2017 - (ACN Newswire) - Proteomics International Laboratories Ltd (PILL; ASX:PIQ) is the leader in predictive diagnostics for diabetic kidney disease, according to an independent Frost & Sullivan report released this month. PILL managing director Dr Richard Lipscombe is in Shanghai this week meeting with possible commercialisation partners for China, and is showcasing PromarkerD at the China-Australia Biotech Investment forum in Shanghai today.
| Managing Director Dr Richard Lipscombe in the PILL Laboratories at Harry Perkins Institute of Medical Research in Perth, Western Australia. |
Dr Lipscombe said the new report, titled Biomarkers Enabling Diabetes and Obesity Management, identifies PromarkerD as the world leader. The report says novel biomarker research is likely to transform the future of obesity and diabetes management.
Frost & Sullivan states that novel tools like PromarkerD can allow enhanced management of obesity, diabetes and related complications in the near future, and goes on to highlight PILL's novel test for diabetic kidney disease noting its high adoption potential.[1]
PromarkerD technology has also been validated by the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).[2]
There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggest PILL is one of only two companies worldwide developing such a test. Results have shown PromarkerD can correctly predict 95% of previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.
PILL already has a deal in place with Chinese biopharmaceutical company Newsummit Biopharma Co. (NSB) to manufacture the PromarkerD kit in China. The process includes engagement of Key Opinion Leaders and Hospitals, who will facilitate validation of the completed kit.
Publication details [1] 'Biomarkers Enabling Diabetes and Obesity Management' published by Frost & Sullivan, March 2, 2017. For the report, http://bit.ly/2nqMfNY. [2] 'Comprehensive Mass Spectrometry Based Biomarker Discovery and Validation Platform as Applied to Diabetic Kidney Disease' published in EuPA Open Proteomics, the official journal of the European Proteomics Association, March 1, 2017. http://bit.ly/2nqMfNY for the research paper.
Multimedia Presentation: An audio summary of the research paper. http://bit.ly/2nqMfNY Video: The power of the Promarker platform for personalised medicine. http://bit.ly/2nqMfNY
PromarkerD - a predictive diagnostic test for diabetic kidney disease -- The EuPA journal article followed evaluation by independent scientific experts and serves to verify the process used to develop and test PILL's PromarkerD protein 'fingerprint? that measures kidney disease in patients with diabetes. This novel test can both diagnose and predict disease.
In diabetic patients already suffering from chronic kidney disease PromarkerD could diagnose the presence of disease that was missed by the current gold standard tests (known as the ACR and eGFR tests).
Critically, PromarkerD can also predict the onset of disease before clinical symptoms appear. In an extension of the published work 576 patients were followed in a four-year longitudinal clinical study. PromarkerD correctly predicted 95% of the previously kidney disease-free diabetic patients who went on to develop chronic kidney disease.
About the Promarker Platform -- PILL's diagnostic research is made possible by the company's proprietary biomarker discovery platform termed Promarker, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a simple blood test. It is a powerful alternative to genetic testing.
The technology is so versatile it can be used to identify fingerprints from any biological source. The Promarker platform is also being applied to the asbestos-related cancer mesothelioma, the gastro-causing parasite Giardia (in partnership with a US veterinary company) and endometriosis, a condition that affects one in ten women in their reproductive years.
About Proteomics International Laboratories (PILL) -- PILL (ASX: PIQ) is a medical technology company focused on proteomics - the industrial scale study of the structure and function of proteins. As proteins have become the drug class of choice for the pharmaceutical industry because of their intimate role in biological systems, proteomics technology is now playing a key role in understanding disease, from finding new diagnostic biomarkers to determining drug targets, and discovering new biopharmaceutical drugs.
PILL is recognised as a global leader in the field of proteomics. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.
The Company's business model uses its proprietary technology platform across three integrated areas, each massive growth markets:
1. Diagnostics: Biomarkers of disease and personalised medicine - focus on diabetic kidney disease. By 2020 the biomarkers market is estimated to double in size to $45.6 billion, and the personalised medicine market is forecast to be worth over $149 billion. 2. Analytical services: Specialist contract research fee-for-service model - focus on biosimilars QC. The global biosimilars market is expected to reach $6.2 billion by 2020, almost trebling from its 2015 level, as it seeks to replicate the multiple billion dollar blockbuster drugs that are coming off patent. 3. Drug discovery: Therapeutic peptide drug discovery - focus on painkillers and antibiotics. The global peptide therapeutics market is currently estimated to be worth $18 billion and is expected to increase by over 10% per year during 2016-2025.
For further information, please visit www.proteomics.com.au, or contact:
Dr Richard Lipscombe Managing Director, Proteomics International Laboratories Ltd E: enquiries@proteomics.com.au T: +61 2 8218 2144
Media Contact: Susan Fitzpatrick-Napier Digital Mantra Group E: team@dmgpr.com T: +61 8 9389 1992
Source: Proteomics International Laboratories Ltd (PILL) Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
Mitsubishi Shipbuilding Receives Order from the University of Tokyo for "MiPoLin" Power Prediction and Lines Selection System Mar 28, 2024 16:45 JST
| Mitsubishi Logisnext Completes Demonstration of Automated Truck Loading, Leading to Start of Actual Operations in Japan Mar 28, 2024 13:52 JST
| Toyota Releases Sales, Production, and Export Results for February 2024 Mar 28, 2024 13:35 JST
| TANAKA to Install 500 kW Fuel Cell System to Promote the Use of Hydrogen Energy at Production Plants Mar 28, 2024 03:00 JST
| PEVE to change name to TOYOTA BATTERY Co., Ltd. and produce batteries for a wide range of electric vehicles Mar 27, 2024 15:13 JST
| NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System Mar 27, 2024 15:00 JST
| TANAKA Holdings Announces Green Loan Financing for Construction of New Head Office Building Mar 27, 2024 03:00 JST
| JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry Mar 26, 2024 19:04 JST
| La Banque Postale and JCB join forces to elevate payments experience for travellers in France Mar 26, 2024 15:00 JST
| Fujitsu Tech Leverages AI and Underwater Drone Data for 'Ocean Digital Twin' Mar 26, 2024 10:24 JST
| NEC develops marketing strategy planning & effectiveness simulation technology using generative AI Mar 25, 2024 10:08 JST
| Toyota to Open New Tokyo Head Office in Shinagawa in FY2030 Mar 22, 2024 16:15 JST
| Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year Mar 22, 2024 16:04 JST
| Mitsubishi Motors Celebrates Production of 100,000th fully electric minivehicle Mar 22, 2024 15:34 JST
| JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card Mar 22, 2024 15:00 JST
| JCB Issues White Paper on Calculating CO2 Emissions by Payment Method in Japan Mar 22, 2024 12:00 JST
| NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber Mar 22, 2024 08:38 JST
| Lifenet and Eisai Co-Develop Dementia Insurance "be" Mar 21, 2024 17:36 JST
| Toyota: Clarification of the Roles of and Expectations for Outside Executives, Revision of the Independence Assessment Criteria, and the Changes to Members of the Board of Directors and the Audit and Supervisory Board Members following the 120th Ordinary General Shareholders' Meeting Mar 21, 2024 16:47 JST
| Sales of Evolved GR Yaris to Start in April, While Purchasing Lotteries for WRC Driver-supervised Special Editions Start Today Mar 21, 2024 16:31 JST
|
More Latest Release >>
|